We report two infants treated with daptomycin for methicillin-resistant Staphylococcus aureus infection and describe peak and trough blood concentrations measured during therapy. The peak concentrations were 41.7 and 36.7 mcg ml À1 , and the 12-hour trough concentrations were 12.7 and 16.3 mcg ml À1 , respectively. Even though the infants received higher doses than adults, their drug concentrations were comparable to those observed in adults treated with regular dosing of daptomycin.
Introduction
Daptomycin is FDA approved for the treatment of complicated skin and skin structure infections, Staphylococcus aureus endocarditis and bacteremia in adult patients. 1 The drug is not FDA approved for use in neonates and there are no reports of its use in this population. The purpose of our study was to describe peak and trough blood concentrations of daptomycin measured in two infants with methicillin-resistant Staphylococcus aureus (MRSA) infection.
Methods
We reviewed the medical records of one neonate and one infant treated with daptomycin for MRSA infection in whom drug concentrations were obtained. Daptomycin blood monitoring is not widely available in clinical practice; the drug concentrations we report were performed by Cubist pharmaceuticals.
Results
The first patient was an infant born by spontaneous vaginal delivery at 23 weeks gestational age with a birth weight of 630 g. At age 2 months, the infant developed MRSA bacteremia. The organism was also resistant to clindamycin, erythromycin and trimethoprim/sulfamethoxazole and it was susceptible to rifampin. Susceptibility to gentamicin was unknown. She had persistently positive blood cultures on day 1, 2 and 6 (on day 4 the blood culture was sterile) despite treatment with vancomycin (trough concentrations of 3.3, 5.8, 7.9, 13 and 19.3 mcg ml À1 on therapy days 2, 4, 6, 7 and 7, respectively) and central line removal on day three of bacteremia. A transthoracic echocardiogram on day 4 of bacteremia revealed a patent foramen ovale with left-to-right shunt and no vegetations. Because of persistent bacteremia, on day 10 she was started on daptomycin 6 mg kg À1 IV every 12 h. Blood cultures drawn 48 h after and immediately before starting daptomycin were sterile. She received a total of 14 days of daptomycin after negative cultures and 7 days of gentamicin as adjunct therapy. Cerebrospinal fluid was not obtained for evaluation of meningitis and chest radiographs obtained throughout the course of therapy did not reveal evidence of pneumonia. Daptomycin peak and trough plasma samples were collected around dose 22. The peak concentration at the end of the 1-h infusion was 41.7 mcg ml À1 and the 12-h trough concentration was 12.7 mcg ml À1 . At the time of sample collection the infant had normal creatinine and blood urea nitrogen values (0.5 and 3 mg dl À1 , respectively). The second patient was a large for gestational age neonate with 11q terminal deletion syndrome born by spontaneous vaginal delivery at 32 weeks with a birth weight of 2670 g. At 3 weeks of age, she developed signs and symptoms consistent with sepsis; however, blood culture was sterile. She was given empirical therapy with vancomycin and gentamicin. After 48 h of vancomycin therapy, she developed a cervical abscess located in the right anterior submandibular space and piperacillin/tazobactam was started. The abscess was excised on day 4 of vancomycin therapy, and MRSA was isolated. The organism was resistant to clindamycin and erythromycin, but was susceptible to trimethoprim/ sulfamethoxazole. This neonate was not evaluated for meningitis and did not have evidence of pneumonia on chest radiograph. She was treated with daptomycin 6 mg kg À1 IV every 12 h for 10 days with resolution of the abscess. After the third dose of daptomycin, the end of the 1-h infusion peak was 36.7 mcg ml À1 and 12-h trough was 16.3 mcg ml À1 . At the time of sample collection the infant had normal creatinine and blood urea nitrogen values (0.5 and 15 mg dl À1 , respectively). Creatine phosphokinase measurements were not obtained for these infants.
Discussion
The peak and trough daptomycin blood concentrations obtained in these infants treated with 6 mg kg À1 every 12 h were consistent with concentrations observed in adults treated with 4 mg kg per dose every 24 h (peak 58 mcg ml À1 , trough 7 mcg ml À1 ).
2
Daptomycin 6 mg kg À1 every day is approved for treatment of MRSA bacteremia.
1 Preliminary data on the pharmacokinetic properties of daptomycin in children older than 2 years of age indicates that an inverse linear correlation exists between clearance and age when young children are compared with adolescents. 3 This observation suggests that infants may require a higher dose of daptomycin when compared to adults. Pharmacokinetic studies of daptomycin in the neonatal population are needed to better establish these differences. Elevated creatine phosphokinase were observed in adults treated with daptomycin, 1 but the effect of this drug in infant skeletal muscle is unknown. These two cases suggest that substantial investigation regarding the PK and safety of daptomycin should be obtained prior to its routine use in the nursery; in the interim, physicians treating infants with daptomycin should consider drug and creatine phosphokinase concentration monitoring.
